Benefiting Subgroup From Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma: A Propensity Score‐Matched Study
Begünstigte Subgruppe durch adjuvante Chemotherapie bei intrahepatischem Cholangiokarzinom: Propensity-Score-gematchte Studie
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72476 ↗Auf einen Blick
Bei resezierten iCCA war adjuvante Chemotherapie mit längerem Gesamtüberleben verbunden. Der Nutzen schien je nach histologischem Subtyp unterschiedlich zu sein.
Fragestellung
Welche Patientengruppe mit reseziertem intrahepatischem Cholangiokarzinom profitiert am ehesten von adjuvanter Chemotherapie?
Methode
Retrospektive Kohortenstudie mit 423 Patient:innen; PSM im Verhältnis 2:1; Analyse von OS mit Kaplan–Meier und Cox-Regression.
Ergebnisse
In der PSM-Kohorte verbesserte ACT das OS gegenüber Beobachtung (HR 0,52; 95 %-KI 0,32–0,82; p = 0,005). Bei small-duct iCCA bestand ein Nutzen (HR 0,33; 95 %-KI 0,17–0,63; p = 0,001), bei large-duct iCCA nicht (HR 0,89; 95 %-KI 0,45–1,76; p = 0,737).
Einschränkungen
Explorative Interaktionsanalysen; die Ergebnisse sollen in unabhängigen prospektiven Kohorten bestätigt werden.
Schlussfolgerung der Autor:innen
Postoperative ACT war nach iCCA-Resektion mit verbessertem OS assoziiert. Der Effekt schien vom histologischen Subtyp abzuhängen, mit stärkerem Nutzen bei small-duct iCCA.
Kernaussagen
- ACT war in der gematchten Kohorte mit besserem OS assoziiert.
- Stärkster Effekt bei small-duct iCCA.
- large-duct iCCA zeigte keinen signifikanten OS-Nutzen.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2026. Verfasst von Yeting Lu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Science and Technology Innovation 2030, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, Clinical Medicine Innovation Team Training Project, Zhejiang University School of Medicine.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The survival benefit of adjuvant chemotherapy (ACT) following resection of intrahepatic cholangiocarcinoma (iCCA) remains controversial; moreover, the patient group that could benefit most from this approach remains undetermined. We conducted a retrospective cohort study of 423 patients (median age 65 years; 52.2% male; 297 patients who received ACT) who underwent curative intent resection of iCCA between 2021 and 2024. To minimize selection bias, propensity score matching (PSM) at a 2:1 ratio was performed. Overall survival (OS) was the primary end point. Survival analyses were conducted using Kaplan–Meier and Cox regression methods. In the PSM‐matched cohort, ACT significantly improved OS compared to observation alone (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.32–0.82, p = 0.005). Subgroup analyses revealed marked heterogeneity in treatment effect. The most remarkable finding was a strong interaction between treatment and histological subtype ( p for interaction = 0.041). Patients with small‐duct type iCCA derived a substantial survival benefit from ACT (HR = 0.33, 95% CI: 0.17–0.63, p = 0.001). In contrast, patients with large‐duct type iCCA did not show a significant OS benefit (HR = 0.89, 95% CI: 0.45–1.76, p = 0.737). In conclusion, postoperative ACT was associated with improved OS after resection of iCCA. Exploratory interaction analyses suggested that the magnitude of this association may differ according to histological subtype, with a more pronounced survival benefit observed in patients with small‐duct type iCCA. These findings should be considered hypothesis‐generating and require confirmation in independent prospective cohorts before histological subtype can be incorporated into treatment‐selection strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, Ningbo Medical Center Lihuili Hospital (The Affiliated Lihuili Hospital, Ningbo University), Ningbo, China.
- Emergency Trauma Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, Shangyu People's Hospital of Shaoxing, Shaoxing University, Shaoxing, China.
- Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
- Zhejiang Provincial Clinical Research Center for the Study of Hepatobiliary and Pancreatic Diseases, Hangzhou, China.
ORCID-Profile: Yeting Lu, Yiwen Chen, Jian Wu, Xueli Bai
Förderung
- the National Science and Technology Innovation 2030, Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China
- Clinical Medicine Innovation Team Training Project, Zhejiang University School of Medicine
Zitieren
APA
Lu, Y., Zhuang, X., Luo, H., Gao, F., Yang, J., Chen, Y., Shen, Y., Zhang, M., Wu, J., Gao, S., Yu, J., Que, R., & Bai, X. (2026). Benefiting Subgroup From Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma: A Propensity Score‐Matched Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72476
Vancouver
Lu Y, Zhuang X, Luo H, Gao F, Yang J, Chen Y, et al. Benefiting Subgroup From Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma: A Propensity Score‐Matched Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72476
BibTeX
@article{Lu2026,
author = {Lu, Yeting and Zhuang, Xinsuo and Luo, Huan and Gao, Fan and Yang, Jiaqi and Chen, Yiwen and Shen, Yan and Zhang, Min and Wu, Jian and Gao, Shunliang and Yu, Jun and Que, Risheng and Bai, Xueli},
title = {Benefiting Subgroup From Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma: A Propensity Score‐Matched Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72476}
}
EUVIMED